Marker Therapeutics, Inc.
A Houston-based clinical-stage biotech company developing T cell-based immunotherapies for blood cancers and solid tumors. Its signature Multi-Antigen Recognizing (MAR) T cell therapy grows a patient's own tumor-fighting T cells in the lab without genetic modification, unlike engineered CAR-T treatments. The company's roots trace to research at Baylor College of Medicine, and its name comes from the tumor "markers" (antigens) its T cells are trained to spot. The current public company was formed in 2018 when TapImmune Inc. merged with the privately held Marker Therapeutics and took on its name.
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.08 Shareholder Director Nominations · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 8.01 Other Events · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
4.01 Changes in Registrant's Certifying Accountant · 9.01 Financial Statements and Exhibits